Endocrine Abstracts

Cushing’s syndrome (CS) is a rare endocrine disease caused by a chronic exposure to endogenous cortisol or exogenous glucocorticoids (GCs). Among multiple comorbidities, impairment of skeletal muscle mass and strength affects 40–70% of patients with active CS and persist even after long-term disease remission. In pathological conditions, GCs excess sustain muscle atrophy and weakness affecting type II muscle fibers. Muscle-specific microRNAs, defined myomiRs, are in...

Background: Improving physical manifestations of hypercortisolism is an important treatment goal for patients with Cushing’s disease (CD). In the Phase III LINC 3 study (NCT02180217), osilodrostat therapy, a potent oral 11β-hydroxylase inhibitor, rapidly normalised mean urinary free cortisol (mUFC) in most patients with CD and sustained control of mUFC over a median treatment period of 130 weeks (W). Here we describe concomitant improvements in physical manifestation...

Introduction: Osilodrostat decreases cortisol production by inhibiting 11β-hydroxylase, increasing adrenal hormones above the blockade. Here, we describe these effects of osilodrostat and associated adverse events (AEs). The efficacy and safety of osilodrostat in patients with Cushing’s disease (CD) were confirmed in the published Phase III, prospective LINC 3 study (NCT02180217).Methods: 137 patients with CD (mUFC >1.5x upper limit of norm...

Background: 24-h mean urinary free cortisol (mUFC) and late-night salivary cortisol (LNSC) levels are complementary parameters recommended for screening and monitoring treatment response in patients with Cushing’s disease (CD). In the published core period of the Phase III LINC 3 study (NCT02180217), therapy with osilodrostat (potent oral 11β-hydroxylase inhibitor) produced rapid, sustained reductions in mUFC and LNSC alongside improvements in clinical signs of hyper...

Purpose: The present study aims to investigate the effects of hyperprolactinemia (HPRL) and its pharmacological control with Cabergoline (CAB) on the risk of fractures in male patients affected by prolactinoma.Methods: Observational single-center study was conducted on 39 male patients (median age 49±12,4 y) with prolactinoma, including 37 with macroprolactinoma and 2 with empty sellae. In patients PRL levels at diagnosis (PRL 0’), PRL at evalu...

Purpose: Dopaminergic system is implicated in the development of sleep disorders, and dopaminergic agents are used in clinical practice to treat daytime sleepiness and sleep disorders. The present study aimed at investigating the effects of hyperprolactinemia and its control with dopamine-agonists (DA) on sleep quality, excessive daytime sleepiness (ESS) and risk of obstructive sleep apnea syndrome (OSAS) in prolactinomas.Methods: A single-centre study w...

Background: In the 22-week LINC-2 study, osilodrostat (LCI699), a potent oral 11β-hydroxylase inhibitor, normalized urinary free cortisol (UFC) levels in 15 of 19 patients with Cushing’s disease (CD). The most common AEs were nausea, diarrhea, asthenia, and adrenal insufficiency (n=6 each). Here, we report the 31-month efficacy and safety results from LINC-2 extension.Methods: Patients receiving clinical benefit at week 22 could enter ...

Introduction: A monthly, long-acting formulation of pasireotide normalized or reduced mean urinary free cortisol (mUFC) in most patients with Cushing’s disease (CD) in a multicentre, double-blind, Phase III study. The effects of long-acting pasireotide on signs and symptoms of CD are reported here.Methods: Patients with persistent/recurrent (n=123) or de novo (non-surgical candidates; n=27) CD and mUFC≥1.5–5xULN...

Introduction: Generously supported by IPSEN)-->Measurement of salivary cortisol is a simple, convenient, accurate and reproducible technique with potential value during the diagnosis/management of hypercortisolism. Current analysis evaluates changes in late-night salivary cortisol (LNSC) during pasireotide treatment in patients with Cushing’s disease (CD).Methods: A 12 m, Phase III study enrolled 162 adult...

Introduction: The clinical features and complications of Cushing’s syndrome result from chronic excess of circulating cortisol, typically quantified by 24-h urinary free cortisol (UFC). LCI699 is a potent inhibitor of 11β-hydroxylase. Since 11β-hydroxylase catalyzes the final step of cortisol synthesis, LCI699 is a potential new treatment for all forms of Cushing’s syndrome.Methods: Adult patients with mild-to-severe Cushing’s di...